How should PCNA be assessed? Total of stained cells or only the most intensely stained ones?
Palavras-chave:
Breast Cancer, Prognostic Factor, Proliferating cell nuclear antigen (PCNA/cyclin)Resumo
Estudou-se o valor prognóstico do antígeno nuclear de proliferação celular (PCNA/Ciclina) em 59 pacientes do Estadio II (T2, N0,1, M0). As pacientes foram separadas de acordo com comprometimento dos linfonodos axilares, com dois grupos, ditos "Axila Positiva" e "Axilia Negativa". Determinou-se a presença do PCNA através do método Avidin-Biotinaperoxidase utilizando o anticorpo monoclonal PC-10. Fez-se a contagem das células no campos mais representativos e contíguos, sempre observando o número de células coradas sobre o total de células contadas, em dois conjuntos, ou seja, total de células coradas e o das mais intensamente coradas. Cotejou-se esses valores com os parâmetros, idade, tamanho do tumor, graus nuclear e histológico e o estado de envolvimento dos linfonodos axilares. Observou-se que o falso juízo e as divergências na avaliação da atividade proliferativa dos tumores podem advir da seleção das amostras, do campo escolhido para contar as células ou dos diferentes aspectos e intensidade consideradas como positivo para o PCNA. Notou-se haver significante associação com valores crescentes da ciclina e a piorea na classificação dos graus nuclear e histológico, em particular, nas pacientes que tinham axila negativa. Sob o ponto de vista prognóstico, a graduação mais elevada do grau nuclear (GN3) e do histológico (GHIII) associaram-se a altos índices de PCNA (>50) e distingüem um grupo de pacientes de alto risco; isto é particularmente importante quando as pacientes têm axila negativa e há necessidade de tratamento sistêmico quimioterápico. Verificou-se ser, essa técnica, simples, reproduzível e facilmente adaptável à rotina laboratorial.
Downloads
Referências
Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978; 121: 2228-33.
Celis EJ, Celis A. Cell-cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S-phase. Proc Natl Acad Sci 1985; 82: 3262- 6.
Bravo R, Frank R, Blundell APP, Macdonad-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-d. Nature 1987; 326:515-17.
Garcia RL, Coltrera MD, Gown AM. Analysis of Proliferative Grade Using Anti-PCNA/Cyclin Monoclonal Antibodies in Fixed, Embedded Tissues. Am J Pathol 1989; 134: 733-39.
Hall AP, Levison AD, Woods LA, Yu WCC, Kellock BD, Watkins AJ, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285-94.
Dawlson AE, Norton JA, Weinberg DS. Comparative assessment of proliferations and DNA content in breast carcinoma by image analysis and flow cytometry. AJP 1990; 136: 1115-24.
Shrestha P, Yamada K, Wada T, Maeda S, Watatani M, Yasutomi M, et al. Proliferating cell nuclear antigen in breast lesions: correlation of c-erb B-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer. Virchows Archiv A Pathol Anat 1992; 421: 193-202.
Aaltomaa S, Lipponen P, Papinaho S, Syrjanen K. Proliferating cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer. J Cancer Rev Clin Oncol 1993; 119: 288-94.
Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, et al. Prognostic value of proliferating cell nuclear antigen in lymph node - negative breast cancer patients. Cancer 1993; 72: 120-5.
Cummings CM, Furnival MC, Parsons GP, Townsend E. PCNA immunostaining in breast cancer. Aust NZJ Surg. 1993; 63: 630-6.
Narita T, Fünahashi H, Satoh Y, Takagi H. Proliferation cell nuclear antigen immunostaining in breast cancer and its relation to prognosis. Jpm J Clin Oncol 1993; 23(1): 20-5.
Tahan RS, Neuberg SD, Dieffenbach A, Yacoub L. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 1993; 71: 3552-9.
Sullivan RP, Mortimer G, Muircheartaigh IO. Cell proliferations in breast tumor: analysis of histological parameters Ki-67 and PCNA expression. IJMS 1993; 162: 343-7.
Thomas M, Noguchi M, Kitagawa H, Kinoshija K, Miyazaki I. Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma. J Clin Pathol 1993; 46: 525-8.
Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 1994; 57: 822-9.
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63:181- 7.
World Health Organization. Histological typing of breast tumors. 2nd.ed.Geneva: WHO; 1981:106.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
Hsu S, Raine L, Fanger H. Use for Avidin-biotin- peroxidase comparison between ABC and unlabelled antibody PAP procedures. J Histochem Cytochem 1981; 29: 557-80.
Siegel S. Estadistica no parametrica. México: Trillas; 1975: 346.
Leonardi E, Girlando S, Serio G, Mauri AF, Perrone G, Scampini S, et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 1992; 45: 416-9.
Siitonen SM, Kallioniemi O, Isola JJ - Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer. AJP 1993; 142: 1081-9.
Haerslav T, Jacobsen GK. Proliferating cell nuclear antigen in breast carcinomas: an immunohistochemical study with correlation to histopathological features and prognostic factors. Virchows Archiv 1994; 424: 39-46.
Fisher B, Redmond C, Fisher E, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from national surgical adjuvant breast and bowel project protocol B-06. J Clin Oncol 1988; 6: 1076-87.
Downloads
Publicado
Como Citar
Edição
Seção
Licença

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.